New Delhi-based pharma manufacturer of oncology and other generic formulations, running three WHO-GMP/US-FDA/EU-GMP plants and exporting to 35+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 14 |
| Reserves | 109 | 121 | 134 | 181 | 194 | 200 | 262 | 262 |
| Borrowings | 11 | 19 | 26 | 26 | 31 | 34 | 39 | 48 |
| Other Liabilities | 49 | 42 | 53 | 59 | 56 | 50 | 53 | 49 |
| Total Liabilities | 181 | 194 | 226 | 279 | 295 | 297 | 367 | 372 |
| AssetsFixed Assets | 34 | 90 | 92 | 93 | 92 | 87 | 86 | 85 |
| CWIP | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 |
| Other Assets | 107 | 104 | 133 | 186 | 203 | 210 | 273 | 287 |
| Total Assets | 181 | 194 | 226 | 279 | 295 | 297 | 367 | 372 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 4 | 13 | 13 | 4 | -6 | -7 | -8 | -33 |
| Cash from Investing | -15 | -37 | -18 | -8 | -6 | -6 | -1 | -3 |
| Cash from Financing | -4 | 19 | 6 | 4 | 29 | 6 | -1 | 64 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -11 | -25 | -5 | -4 | -13 | -13 | -10 | -38 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (77.4×) and current (32.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -16.4% growth and a 33× exit, ₹239 only delivers your return if you pay ₹37. The price is currently baking in 18% growth.
EPS grows -16.4%/yr for 5 years, then fades to 6% over 2, exits at 33×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -16.4% | 6.06 |
| FY28 | -16.4% | 5.07 |
| FY29 | -16.4% | 4.24 |
| FY30 | -16.4% | 3.54 |
| FY31 | -16.4% | 2.96 |
| FY32 | -5.2% ·fade | 2.81 |
| FY33 | 6.0% ·fade | 2.97 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.